Frank Bretz "How the ICH E9 addendum around estimands may impact our clinical trials (KN2)" скачать в хорошем качестве

Frank Bretz "How the ICH E9 addendum around estimands may impact our clinical trials (KN2)"

Ausschnittfassung. Den kompletten Vortrag können Sie im exklusiven GMDS-Mitgliederbereich sehen (GMDS-Intranet, Bild- und Videomaterial) Teaser version. You can view the complete presentation in the exclusive GMDS member area (GMDS intranet, image and video material) Erfahren Sie mehr über die GMDS: https://gmds.de/ Keynote-Vortrag im Rahmen der GMDS-Jahrestagung 2018 in Osnabrück The way we think about clinical trial design, conduct and analysis is likely to undergo a step-change, due to the much anticipated release of the draft ICH E9 addendum on estimands. Importantly, this topic is not only statistical. It is a multidisciplinary effort that requires a common understanding and buy-in beyond the statistics community. Prior to the release of the fnal guidance document, expected in mid-2019, this presentation will discuss where we currently stand and postulate on possible future directions. Frank Bretz, PhD is a Novartis Distinguished Scientist and VP, Head Statistical Methodology and Consulting at Novartis Pharma AG Switzerland.